The Impact of Cand1 in Prostate Cancer

The Impact of Cand1 in Prostate Cancer

Evidence has accumulated asserting the importance of cullin-RING (really interesting new gene) ubiquitin ligases (CRLs) and their regulator Cullin-associated neural-precursor-cell-expressed developmentally down-regulated 8 (NEDD8) dissociated protein 1 (Cand1) in various cancer entities. However, th...

Full description

Bibliographic Details
Main Authors:	Andrea Eigentler, Piotr Tymoszuk, Johanna Zwick, Arndt A. Schmitz, Andreas Pircher, Florian Kocher, Andreas Schlicker, Ralf Lesche, Georg Schäfer, Igor Theurl, Helmut Klocker, Isabel Heidegger
Format:	Article
Language:	English
Published:	MDPI AG 2020-02-01
Series:	Cancers
Subjects:	prostate cancer cand1 cancer aggressiveness survival tumor recurrence mutation enzalutamide resistance
Online Access:	https://www.mdpi.com/2072-6694/12/2/428

Similar Items

Colônia Agrícola Nacional de Dourados – história, memória: considerações acerca da construção de uma memória oficial sobre a CAND na região da Grande Dourados
by: Ana Paula Menezes
Published: (2011-06-01)

CAND2/PMTR1 Is Required for Melatonin-Conferred Osmotic Stress Tolerance in Arabidopsis
by: Lin-Feng Wang, et al.
Published: (2021-04-01)

La place de la collégiale de Candes-Saint-Martin dans l'ouest de la France
by: Boissenot, Claude
Published: (2011)

Predominance of Cand. Patescibacteria in Groundwater Is Caused by Their Preferential Mobilization From Soils and Flourishing Under Oligotrophic Conditions
by: Martina Herrmann, et al.
Published: (2019-06-01)

"MARQUEI AQUELE LUGAR COM O SUOR DO MEU ROSTO : Os colonos da Colônia Agrícola Nacional de Dourados - CAND (1943 -1960)
by: Naglis, Suzana Gonçalves Batista
Published: (2016)

Candes-Saint-Martin et ses cimetières : évolution de son organisation spatiale, depuis l’Antiquité jusqu’à l’époque Moderne (Région Centre, Indre-et-Loire)
by: Stéphanie Philippon, et al.
Published: (2015-04-01)

Integration of Fungus-Specific CandA-C1 into a Trimeric CandA Complex Allowed Splitting of the Gene for the Conserved Receptor Exchange Factor of CullinA E3 Ubiquitin Ligases in Aspergilli
by: Anna M. Köhler, et al.
Published: (2019-06-01)

Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-07-01)

Pharmacoeconomic analysis of enzalutamide and abiraterone for treatment of chemotherapy naive patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2017-10-01)

A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research
by: Laccetti AL, et al.
Published: (2020-12-01)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
by: Hall ME, et al.
Published: (2020-04-01)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
by: Taro Iguchi, et al.
Published: (2019-04-01)

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer
by: Rosanne CV. Van der Roest, et al.
Published: (2016-07-01)

Specific ubiquitin-dependent protein degradation requires a trimeric CandA complex in Aspergillus nidulans
by: Köhler, Anna Maria
Published: (2019)

Etude du rôle du récepteur des androgènes dans le cancer du sein apocrine moléculaire
by: Barritault, Marc
Published: (2016)

Safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: a phase II, multicenter, single-arm, open-label study
by: B. Ya. Alekseev, et al.
Published: (2018-04-01)

THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
by: Pravien Rajaram, et al.
Published: (2020-05-01)

Splice variants of androgen receptor and prostate cancer
by: Orazio Caffo, et al.
Published: (2016-05-01)

AR mRNA stability is increased with AR-antagonist resistance via 3′UTR variants
by: D A Dart, et al.
Published: (2019-12-01)

Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis
by: Joana Simões, et al.
Published: (2018-06-01)

Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study
by: Huanyi Lin, et al.
Published: (2021-04-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01)

Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer
by: Yongjun Quan, et al.
Published: (2019-12-01)

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
by: Mona Kafka, et al.
Published: (2020-07-01)

New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer
by: B. Ya. Alekseev
Published: (2019-10-01)

Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2020-07-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)

A review of new hormonal therapies for prostate cancer in black men: is there enough data?
by: Matthias E. Meunier, et al.
Published: (2021-01-01)

Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer
by: R. William Watson, et al.
Published: (2020-11-01)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
by: Peng-Fei Zhang, et al.
Published: (2021-01-01)

Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review
by: Laura Marandino, et al.
Published: (2020-09-01)

DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity
by: Nicolas Malaquin, et al.
Published: (2020-07-01)

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience
by: Rachel Raju, et al.
Published: (2021-06-01)

NEW TREATMENT STANDARD FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
by: B. Ya. Alekseev
Published: (2018-10-01)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
by: Magdalena Staniszewska, et al.
Published: (2021-07-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
by: Timothy C. Wright, et al.
Published: (2021-07-01)

Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1
by: Lijie Zhou, et al.
Published: (2021-06-01)

SWATH-MS Based Proteomic Profiling of Prostate Cancer Cells Reveals Adaptive Molecular Mechanisms in Response to Anti-Androgen Therapy
by: Chamikara Liyanage, et al.
Published: (2021-02-01)

Histone Demethylase LSD1 Regulates Kidney Cancer Progression by Modulating Androgen Receptor Activity
by: Kyoung-Hwa Lee, et al.
Published: (2020-08-01)